Join
Live feed
·
PRReleasevia Quantisnow
Korro Bio Inc. logo

Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

ByQuantisnow·Wall Street's wire, on your screen.
KRRO· Korro Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KRRO (Korro Bio Inc.) and more on Quantisnow.